Human epidermal growth factor receptor 2 peptide epitope presentation via MHC class I pathway

The phrase "Human epidermal growth factor receptor 2 peptide epitope presentation via MHC class I pathway" refers not to a single molecular target or receptor, but rather describes the process by which peptides derived from the human epidermal growth factor receptor 2 (HER2, also known as ERBB2) are processed inside cells and presented on their surface bound to major histocompatibility complex (MHC) class I molecules. This process enables cytotoxic CD8+ T cells of the immune system to recognize and potentially eliminate tumor cells expressing abnormal levels or mutant forms of HER2. In detail: 1. Proteasomal degradation breaks down intracellular proteins—including overexpressed or mutated HER2—into short peptides. 2. These peptides are transported into the endoplasmic reticulum by TAP transporters. 3. Peptides fitting certain length and sequence criteria bind newly assembled MHC class I molecules. 4. The resulting HER2-derived peptide–MHC-I complexes travel through the Golgi apparatus to be displayed on the cell surface. 5. Cytotoxic T lymphocytes may then recognize these complexes if they display non-self antigens (e.g., mutated sequences), leading to targeted killing of cancerous cells. This mechanism underlies many cancer immunotherapies that aim either at enhancing tumor antigen visibility through improved antigen processing/presentation, or at directly targeting overexpressed receptors like HER2. However, "Human epidermal growth factor receptor 2 peptide epitope presentation via MHC class I pathway" is not itself a canonical molecular target—it describes an immunological event involving multiple proteins/machineries rather than one discrete druggable entity. If you seek structured information about actual targets involved in this process, consider focusing on: | Canonical Name | Abbreviation | Is Target | |------------------------------------------------|--------------|-----------| | Human epidermal growth factor receptor 2 | HER2 | true | | Major histocompatibility complex class I | HLA-A/B/C | true | | Transporter associated with antigen processing | TAP | true | But as written ("...epitope presentation..."), it does not correspond directly with any recognized therapeutic target. In summary: This entry represents an important biological mechanism relevant for cancer immunity—not an individual molecule/receptor suitable for direct drug targeting.

Other names

HER2 peptide epitope presentation via MHC class IERBB2 antigen processing and presentation (via MHC-I)HER2/neu-derived peptide-MHC class I complex